Logo of TCD Capital, which leads to the homepage when clicked.

Nyxoah, a company developing disruptive neurostimulation technology to cure obstructive sleep apnea, mandated TCD Capital for supporting a capital increase. Established in Mont Saint Guibert, with R&D in Tel Aviv, Israel, the Company managed to close the capital increase, with a new Lead Investor, a Dutch Private Equity Fund and the existing club of shareholders.

That substantial capital increase allows the Company to have a new horizon up to the end of the CE marking phase, a substantial milestone in value creation.

At TCD Capital, we have supported more capital developments or invested into med and biotech, where Belgium based ventures consistently demonstrates a leadership. The strategy to market, the disruptive impact of the solution, the importance of the market place it addresses are all factors which may validate an investment option.

Subscribe to our Newsletter

We seek to customise the content to the segments we serve.

These are both fund investors and the entrepreneurs with whom we have created alliances.

We are happy to keep in touch.

TCD Form Template Style